Publications by authors named "Robert Pirker"

100Publications

mutation tracking predicts survival in advanced -mutated non-small cell lung cancer patients treated with osimertinib.

Transl Lung Cancer Res 2020 Apr;9(2):239-245

Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2020.03.02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225165PMC
April 2020

Beyond tissue biopsy: a diagnostic framework to address tumor heterogeneity in lung cancer.

Curr Opin Oncol 2020 01;32(1):68-77

Department of Biomedical Imaging and Image-Guided Therapy Medical University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000598DOI Listing
January 2020

Editorial: Individualizing treatment of nonsmall cell lung cancer.

Authors:
Robert Pirker

Curr Opin Oncol 2020 01;32(1):35-36

Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000597DOI Listing
January 2020

Chemotherapy remains a cornerstone in the treatment of nonsmall cell lung cancer.

Authors:
Robert Pirker

Curr Opin Oncol 2020 01;32(1):63-67

Department of Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000592DOI Listing
January 2020

From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer.

ESMO Open 2019 8;4(5):e000548. Epub 2019 Sep 8.

Internal Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2019-000548DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735665PMC
September 2019

Systemic therapy of elderly patients with advanced non-small cell lung cancer-individualized treatment is key.

Authors:
Robert Pirker

Ann Transl Med 2019 Mar;7(Suppl 1):S48

Department of Medicine I, Medical University Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2019.03.10DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462625PMC
March 2019

EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR.

Target Oncol 2019 04;14(2):197-203

Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, 1090, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-019-00623-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6453866PMC
April 2019

Biomarkers for immune checkpoint inhibitors in advanced nonsmall cell lung cancer.

Authors:
Robert Pirker

Curr Opin Oncol 2019 01;31(1):24-28

Department of Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000496DOI Listing
January 2019

Management of stage IA -mutant adenocarcinoma of the lung.

Authors:
Robert Pirker

J Thorac Dis 2018 Sep;10(Suppl 26):S3260-S3262

Department of Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2018.08.70DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186648PMC
September 2018

Adjuvant Therapy in Patients With Completely Resected Non-small-cell Lung Cancer: Current Status and Perspectives.

Clin Lung Cancer 2019 01 24;20(1):1-6. Epub 2018 Sep 24.

Department of Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183026
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.09.016DOI Listing
January 2019

Treatment of Advanced Non-Small-Cell Lung Cancer: From Chemotherapy to Chemoimmunotherapy.

Authors:
Robert Pirker

J Oncol Pract 2018 09;14(9):537-538

Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JOP.18.00474
Publisher Site
http://dx.doi.org/10.1200/JOP.18.00474DOI Listing
September 2018

PD-1 and PD-L1 Protein Expression Predict Survival in Completely Resected Lung Adenocarcinoma.

Clin Lung Cancer 2018 11 22;19(6):e957-e963. Epub 2018 Aug 22.

Institute of Cancer Research, Medical University of Vienna, Vienna, Austria; Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.08.014DOI Listing
November 2018

Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer?

Authors:
Robert Pirker

ESMO Open 2018 10;3(5):e000421. Epub 2018 Aug 10.

Department of Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2018-000421DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6088342PMC
August 2018

Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives.

Memo 2018 18;11(2):112-115. Epub 2018 May 18.

Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12254-018-0408-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006273PMC
May 2018

Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer.

Haematologica 2018 09 24;103(9):1549-1556. Epub 2018 May 24.

Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Austria

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.192419DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119137PMC
September 2018

Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC.

J Thorac Oncol 2018 06 2;13(6):821-830. Epub 2018 Mar 2.

Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical Center of Vienna, Vienna, Austria. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864183016
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2018.02.014DOI Listing
June 2018

EGFR monoclonal antibody biomarkers in advanced NSCLC: from translational research to clinical implementation.

Authors:
Robert Pirker

Lancet Oncol 2018 01 20;19(1):10-12. Epub 2017 Nov 20.

Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30873-2DOI Listing
January 2018

Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.

J Clin Oncol 2017 Jun 28;35(18):2018-2027. Epub 2017 Apr 28.

Frances A. Shepherd and Ming-Sound Tsao, Princess Margaret Cancer Centre; University of Toronto, Toronto; Lesley Seymour, Queen's University, Kingston, Ontario, Canada; Benjamin Lacas, Gwénaël Le Teuff, Jean-Pierre Pignon, Thierry Le Chevalier, and Jean-Charles Soria, Institut Gustave-Roussy; Benjamin Lacas, Gwénaël Le Teuff, Jean-Pierre Pignon, Thierry Le Chevalier, and Jean-Charles Soria, University Paris XI, Paris; Pierre Hainaut, International Agency for Research on Cancer, Lyon; Jean-Yves Douillard, R Gauducheau, St Herblain; Elizabeth Brambilla, Inserm U823, Institut Albert Bonniot, Département de Pathologie CHU, Albert Michallon University Joseph Fourrier, Grenoble, France; Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA; Stephen Graziano, State University of New York Upstate Medical University, Syracuse, NY; Robert Kratzke, University of Minnesota Medical School, Minneapolis, MN; and Robert Pirker and Martin Filipits, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.2893DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075828PMC
June 2017

Trimodality therapy for Pancoast tumors: T4 is not a contraindication to radical surgery.

J Surg Oncol 2017 Aug 13;116(2):227-235. Epub 2017 Apr 13.

Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jso.24629DOI Listing
August 2017

Molecular Biomarkers in Advanced Non-Small-Cell Lung Cancer: A Rapidly Changing Field.

Authors:
Robert Pirker

J Oncol Pract 2017 04;13(4):231-232

Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2017.022780DOI Listing
April 2017

Milestones in the systemic treatment of lung cancer.

Authors:
Robert Pirker

Memo 2017 6;10(1):22-26. Epub 2017 Feb 6.

Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12254-017-0313-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357246PMC
February 2017

Palliative care units in lung cancer in the real-world setting: a single institution's experience and its implications.

Ann Palliat Med 2017 Jan 1;6(1):6-13. Epub 2016 Sep 1.

Clinical Division of Palliative Care, Department of Internal Medicine I, Medical University of Vienna, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/apm.2016.08.06DOI Listing
January 2017

Improving survival of patients with locally advanced non-small-cell cancer remains a challenge: comment to PROCLAIM.

Authors:
Robert Pirker

J Thorac Dis 2016 Jul;8(7):E607-10

Department of Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2016.05.54DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4958816PMC
July 2016

Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice.

Cancer Metastasis Rev 2016 Mar;35(1):141-50

Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-016-9612-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821865PMC
March 2016

Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis.

J Thorac Oncol 2016 06 17;11(6):850-61. Epub 2016 Feb 17.

International Agency for Research on Cancer, Lyon, France; Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada; Department of Pathology, Centre Hospitalier Universitaire, Grenoble, France; International Prevention Research Institute, Lyon, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.02.002DOI Listing
June 2016

Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer.

J Clin Oncol 2016 Apr 1;34(11):1223-30. Epub 2016 Feb 1.

Elisabeth Brambilla and Sylvie Lantuejoul, Institut Albert Bonniot-Institut National de la Santé et de la Recherche Médicale U823; and Centre Hospitalier Universitaire Albert Michallon, Grenoble; Gwénaël Le Teuff, Sophie Marguet, Ariane Dunant, Thierry Le Chevalier, and Jean-Charles Soria, Institut Gustave Roussy, Villejuif; Gwénaël Le Teuff, Sophie Marguet, Ariane Dunant, Thierry Le Chevalier, and Jean-Charles Soria, Université Paris-Sud, Orsay; Gwénaël Le Teuff, Université Paris-Saclay, Saint-Aubin; Jean-Yves Douillard, Centre René Gauducheau Institut de Cancerologie de l'Ouest, Saint-Herblain, France; Stephen Graziano, State University of New York Upstate Medical University, Syracuse, NY; Robert Pirker and Martin Filipits, Medical University of Vienna, Vienna; Helmut Popper, Medical University of Graz, Graz, Austria; Rafael Rosell, Catalan Institute of Oncology, Barcelona, Spain; Robert Kratzke, University of Minnesota, Minneapolis, MN; Frances A. Shepherd and Ming Sound Tsao, Princess Margaret Cancer Centre; Frances A. Shepherd and Ming Sound Tsao, University of Toronto, Toronto; and Lesley Seymour, Queen's University, Kingston, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.0970DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872323PMC
April 2016

Alectinib in RET-rearranged non-small cell lung cancer-Another progress in precision medicine?

Transl Lung Cancer Res 2015 Dec;4(6):797-800

Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2015.03.08DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700226PMC
December 2015

Effectiveness of Darbepoetin Alfa for Chemotherapy-induced Anemia When Initiated at Hemoglobin ≤10 g/dL.

Clin Ther 2016 Jan 22;38(1):122-135.e6. Epub 2015 Dec 22.

Medical, Amgen Switzerland AG, Zug, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinthera.2015.11.012DOI Listing
January 2016

Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.

Authors:
Robert Pirker

Curr Opin Oncol 2016 Mar;28(2):115-21

Department of Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000260DOI Listing
March 2016

Adjuvant chemotherapy in patients with completely resected non-small cell lung cancer.

Authors:
Robert Pirker

Transl Lung Cancer Res 2014 Oct;3(5):305-10

Department of Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2014.09.13DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367797PMC
October 2014

Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update.

Authors:
Robert Pirker

Curr Opin Oncol 2015 Mar;27(2):87-93

Department of Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000162DOI Listing
March 2015

Perspectives of novel imaging techniques for staging, therapy response assessment, and monitoring of surveillance in lung cancer: summary of the Dresden 2013 Post WCLC-IASLC State-of-the-Art Imaging Workshop.

J Thorac Oncol 2015 Feb;10(2):237-49

*Institute of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; †Division of Thoracic Surgery, Royal Brompton Hospital, Imperial College London, London, United Kingdom; ‡Department of Radiation Oncology, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; §Department of Medicine I, Medical University of Vienna, Vienna, Austria; ║Division of Thoracic Surgery, University Hospital of Zurich, Zurich, Switzerland; ¶Medical Oncology Division, Department of Oncology, University Hospital Perugia, Perugia, Italy; #Lung Cancer Research, University of Leicester & Leicester University Hospitals, Leicester, United Kingdom; **Department of Radiology, General Hospital Celle, Celle, Germany; ††Department of Thoracic and Vascular Surgery, Hôpital Tenon, University of Paris VI, Paris, France; ‡‡Department of Surgery/Thoracic Oncology, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; §§Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; ║║Department of Radiation Oncology, VU University Medical Center Amsterdam, Amsterdam, The Netherlands; ¶¶Department of Pneumology, Respiratory Oncology Unit and Trial Unit, University Hospital KU Leuven, Leuven, Belgium; ##Clinical Competence Center Oncology, Siemens AG, Erlangen, Germany; ***Institute of Clinical Radiology and Nuclear Medicine/Department of Molecular Imaging & Radiopharmacy, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; †††Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000412DOI Listing
February 2015

What is the best strategy for targeting EGF receptors in non-small-cell lung cancer?

Authors:
Robert Pirker

Future Oncol 2015 ;11(1):153-67

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.14.178DOI Listing
September 2015

Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer.

J Thorac Oncol 2014 May;9(5):717-24

*Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Centre René Gauducheau, Saint-Herblain, France; †Department of Medicine I, Medical University of Vienna, Vienna, Austria; ‡HOPE Directorate, St James's Hospital, Dublin, Ireland; §Department of Pathology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; ‖Institute of Pathology, University of Witten/Herdecke and HELIOS Hospital Wuppertal, Wuppertal, Germany; ¶Global Biostatistics, #Biomarker Technologies & Operations, and **Translational Innovation Platform Oncology, Merck KGaA, Darmstadt, Germany; and ††University Health Network, Department of Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000141DOI Listing
May 2014

Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer.

Mol Oncol 2014 May 15;8(3):555-64. Epub 2014 Jan 15.

University of Strathclyde School of Global Public Health at iPRI, International Prevention Research Institute, Lyon, France; Institut Albert Bonniot, Institut National de la Santé et de la Recherche Médicale U 823, Grenoble, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2013.12.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528648PMC
May 2014

Novel drugs against non-small-cell lung cancer.

Authors:
Robert Pirker

Curr Opin Oncol 2014 Mar;26(2):145-51

Department of Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000056DOI Listing
March 2014

Epidermal growth factor receptor inhibition in lung cancer: status 2012.

J Thorac Oncol 2013 Mar;8(3):373-84

Department of Medicine, Division of Medical Oncology and Department of Pathology, University of Colorado Cancer Center, 12801 E. 17th Avenue, Aurora, CO 80045, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e31827ed0ffDOI Listing
March 2013

EGFR-directed monoclonal antibodies in non-small cell lung cancer.

Authors:
Robert Pirker

Target Oncol 2013 Mar 9;8(1):47-53. Epub 2013 Jan 9.

Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-012-0244-7DOI Listing
March 2013

EGFR-directed monoclonal antibodies in non-small cell lung cancer: how to predict efficacy?

Authors:
Robert Pirker

Transl Lung Cancer Res 2012 Dec;1(4):269-75

Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2012.10.09DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367547PMC
December 2012

High D-dimer levels are associated with poor prognosis in cancer patients.

Haematologica 2012 Aug 27;97(8):1158-64. Epub 2012 Feb 27.

Clinical Division of Hematology and Hemostaseology Department of Medicine I, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2011.054718DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3409812PMC
August 2012

Cetuximab in non-small-cell lung cancer.

Transl Lung Cancer Res 2012 Mar;1(1):54-60

Department of Medicine I, Medical University Vienna, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.11.01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367590PMC
March 2012

Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses.

Lung Cancer 2012 Jun 25;76(3):478-85. Epub 2012 Jan 25.

Respiratory Oncology Unit (Pulmonology), University Hospital Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S016950021100679
Publisher Site
http://dx.doi.org/10.1016/j.lungcan.2011.12.015DOI Listing
June 2012

Adjuvant chemotherapy of non-small cell lung cancer.

Authors:
Robert Pirker

Tanaffos 2012 ;11(1):12-7

Department of Medicine I, Medical University Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153177PMC
September 2014

The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.

J Clin Pathol 2012 Jan 29;65(1):1-7. Epub 2011 Oct 29.

Department of Clinical Medicine, Institute of Molecular Medicine, St James's Hospital, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2011-200275DOI Listing
January 2012

Chemotherapy: advanced NSCLC--should we use doublets in elderly patients?

Authors:
Robert Pirker

Nat Rev Clin Oncol 2011 Sep 27;8(12):694-6. Epub 2011 Sep 27.

Department of Medicine I, Medical University Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2011.147DOI Listing
September 2011

Predictive markers in the adjuvant therapy of non-small cell lung cancer.

Lung Cancer 2011 Dec 31;74(3):355-63. Epub 2011 Aug 31.

Department of Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2011.06.005DOI Listing
December 2011

Monoclonal antibodies against EGFR in non-small cell lung cancer.

Crit Rev Oncol Hematol 2011 Oct 24;80(1):1-9. Epub 2010 Nov 24.

Department of Medicine I, Medical University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2010.10.008DOI Listing
October 2011

Bevacizumab in lung cancer: hurdles in clinical development.

Authors:
Robert Pirker

Lancet Oncol 2010 Aug 23;11(8):703-4. Epub 2010 Jul 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(10)70173-XDOI Listing
August 2010

MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer.

Clin Cancer Res 2010 Feb 9;16(4):1206-15. Epub 2010 Feb 9.

Department of Medicine, Biostatistics and Epidemiology Unit, Translational Research Laboratory, Paris-Sud University, Gustave-Roussy Institute, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-2204DOI Listing
February 2010

Chemotherapy of advanced non-small cell lung cancer.

Front Radiat Ther Oncol 2010 24;42:157-163. Epub 2009 Nov 24.

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/262471
Publisher Site
http://dx.doi.org/10.1159/000262471DOI Listing
March 2010

Erythropoiesis-stimulating agents in patients with cancer: update on safety issues.

Authors:
Robert Pirker

Expert Opin Drug Saf 2009 Sep;8(5):515-22

Medical University of Vienna, Department of Medicine I, Währinger Gürtel 18-20, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14740330903158929DOI Listing
September 2009

EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.

Clin Cancer Res 2009 Jul 7;15(14):4554-60. Epub 2009 Jul 7.

Clinical Institute of Pathology and Department of Medicine I, Medical University of Vienna, Waehringer Guertel 18-20, Vienna A-1090, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-0089DOI Listing
July 2009

Targeted therapies in lung cancer.

Curr Pharm Des 2009 ;15(2):188-206

Department of Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138161209787002915DOI Listing
March 2009

Cetuximab: potential role as first-line treatment for advanced non-small cell lung cancer.

Authors:
Robert Pirker

Clin Adv Hematol Oncol 2008 Oct;6(10):735-6

Department of Medicine 1, Medical University of Vienna, Austria.

View Article

Download full-text PDF

Source
October 2008

Erythropoietin in cancer: an update.

Curr Mol Med 2008 Sep;8(6):481-91

Department of Tumor Biology, National Koranyi Institute of Pulmonology, Piheno u 1, Budapest, H-1529, Hungary.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/156652408785747979DOI Listing
September 2008

Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide.

J Clin Oncol 2008 May;26(14):2342-9

Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.15.0748DOI Listing
May 2008

Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.

Clin Lung Cancer 2008 ;9 Suppl 3:S109-15

Department of Internal Medicine I, Medical University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CLC.2008.s.016DOI Listing
December 2009

Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer.

Breast Cancer Res Treat 2007 Jul 27;103(3):283-91. Epub 2007 Jan 27.

Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-006-9377-7DOI Listing
July 2007

Safety considerations for erythropoietin treatment in patients with cancer.

Authors:
Robert Pirker

Expert Opin Drug Saf 2007 Jan;6(1):63-9

Lung Cancer, Medical University of Vienna, Department of Internal Medicine I, Währinger Gürtel 18-20, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1517/14740338.6.1.63
Publisher Site
http://dx.doi.org/10.1517/14740338.6.1.63DOI Listing
January 2007

Once-weekly epoetin beta (30,000 IU) in anemic patients with lung cancer receiving chemotherapy.

Lung Cancer 2007 Jan 3;55(1):89-94. Epub 2006 Nov 3.

Department of Internal Medicine I, Medical University Vienna, Währinger Gürtel 18, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2006.09.020DOI Listing
January 2007